Table IV.
Studies available on RTX administration in children with SDNS or FRNS.
| Study (author, year) | No. of cases | Time of RTX | Follow-up | Co-drugs | Efficiency (%) | Refs. |
|---|---|---|---|---|---|---|
| Iijima et al, 2014 | 24 | 375 mg/m2/time | 53 weeks | Pred | 14/24 (58.3) | (9) |
| FRNS/SDNS | Once a week for 4 week | |||||
| Sun et al, 2014 | 9 for SSNS | 375 mg/m2/time | 4–16 months | Pred | 5/9 (55.6) | (14) |
| 2 for SRNS | One or two times | |||||
| Ravani et al, 2013 | 46 | 375 mg/m2/time | >3 years | Pred and CsA | 22/46 (48.0) | (6) |
| SDNS | One to five times | |||||
| Ito et al, 2013 | 53 | 375 mg/m2/time | 8–51 months | Pred or CsA | 41/53 (77.0) | (15) |
| SDNS/FRNS | One or more times | |||||
| Tellier et al, 2013 | 18 | 375 mg/m2/time | Median 3.2 years | Pred | 8/18 (44.5) | (16) |
| SDNS | One to four times | |||||
| Sellier-Leclerc et al, 2012 | 30 | 375 mg/m2/time | >24 months | Pred or MMF or CsA | 19/30 (63.3) | (17) |
| SDNS | One to four times | |||||
| Kemper et al, 2012 | 29/37 | 375 mg/m2/time | >24 months | Pred or CI or MPI | 7/29 (24.1) | (18) |
| SDNS | Once a week for 1 to 4 weeks | |||||
| Ravani et al, 2011 | 54 | 375 mg/m2/time | >9 months | Pred and CsA | 27/54 (50.0) | (19) |
| SDNS | One or two times | |||||
| Fujinaga et al, 2010 | 10 | 375 mg/m2/time | 17 months | CsA | 5/10 (50.0 | (10) |
| MCD, SDNS | One time | |||||
| Sellier-Leclerc et al, 2010 | 22 | 375 mg/m2/time | 3.2–28.5 months | Pred or CsA | 9/22 (41.0) | (20) |
| SDNS | One or two times | |||||
| Prytuła et al, 2010 | 28 | 375 mg/m2/time | 1–16 months | Pred | 10/28 (35.7) | (13) |
| SDNS/FRNS | One to five times | |||||
| Kamei et al, 2009 | 12 | 375 mg/m2/time | >12 months | Pred | 3/12 (25.0) | (7) |
| SDNS | One time |
RTX, rituximab; FRNS, frequently relapsing nephrotic syndrome; SDNS, steroid-dependent nephrotic syndrome; SSNS, steroid-sensitive nephrotic syndrome; SRNS, steroid-resistance nephrotic syndrome; MPA, mycophenolic acid; Pred, prednisone; CI, calcineurin inhibitors.